These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24928849)

  • 61. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
    Zhang Y; Hansen JK; Xiang L; Kawa S; Onda M; Ho M; Hassan R; Pastan I
    Cancer Res; 2010 Feb; 70(3):1082-9. PubMed ID: 20103626
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
    Mossoba ME; Onda M; Taylor J; Massey PR; Treadwell S; Sharon E; Hassan R; Pastan I; Fowler DH
    Clin Cancer Res; 2011 Jun; 17(11):3697-705. PubMed ID: 21521777
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines.
    Maurici CE; Colenbier R; Wylleman B; Brancato L; van Zwol E; Van den Bossche J; Timmermans JP; Giovannetti E; Mori da Cunha MGMC; Bogers J
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625581
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products.
    Guzmán EA; Harmody D; Pitts TP; Vera-Diaz B; Winder PL; Yu Y; Wright AE
    Anticancer Drugs; 2017 Feb; 28(2):153-160. PubMed ID: 27749658
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.
    Gulhati P; Schalck A; Jiang S; Shang X; Wu CJ; Hou P; Ruiz SH; Soto LS; Parra E; Ying H; Han J; Dey P; Li J; Deng P; Sei E; Maeda DY; Zebala JA; Spring DJ; Kim M; Wang H; Maitra A; Moore D; Clise-Dwyer K; Wang YA; Navin NE; DePinho RA
    Nat Cancer; 2023 Jan; 4(1):62-80. PubMed ID: 36585453
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
    Alewine C; Xiang L; Yamori T; Niederfellner G; Bosslet K; Pastan I
    Mol Cancer Ther; 2014 Nov; 13(11):2653-61. PubMed ID: 25239937
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
    Hollevoet K; Mason-Osann E; Müller F; Pastan I
    PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advances in anticancer immunotoxin therapy.
    Alewine C; Hassan R; Pastan I
    Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
    Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
    Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
    Bera TK; Onda M; Kreitman RJ; Pastan I
    Leuk Res; 2014 Oct; 38(10):1224-9. PubMed ID: 25127689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.
    Mason-Osann E; Hollevoet K; Niederfellner G; Pastan I
    Sci Rep; 2015 Jun; 5():10832. PubMed ID: 26111884
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
    Meneses-Lorente G; Friess T; Kolm I; Hölzlwimmer G; Bader S; Meille C; Thomas M; Bossenmaier B
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):837-50. PubMed ID: 25702049
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.
    Chantrill LA; Nagrial AM; Watson C; Johns AL; Martyn-Smith M; Simpson S; Mead S; Jones MD; Samra JS; Gill AJ; Watson N; Chin VT; Humphris JL; Chou A; Brown B; Morey A; Pajic M; Grimmond SM; Chang DK; Thomas D; Sebastian L; Sjoquist K; Yip S; Pavlakis N; Asghari R; Harvey S; Grimison P; Simes J; Biankin AV; ;
    Clin Cancer Res; 2015 May; 21(9):2029-37. PubMed ID: 25896973
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
    Lindenberg L; Thomas A; Adler S; Mena E; Kurdziel K; Maltzman J; Wallin B; Hoffman K; Pastan I; Paik CH; Choyke P; Hassan R
    Oncotarget; 2015 Feb; 6(6):4496-504. PubMed ID: 25756664
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity.
    Pasetto M; Antignani A; Ormanoglu P; Buehler E; Guha R; Pastan I; Martin SE; FitzGerald DJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1135-42. PubMed ID: 25713356
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model.
    Pak Y; Pastan I; Kreitman RJ; Lee B
    PLoS One; 2014; 9(10):e110716. PubMed ID: 25343405
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.
    Manning ML; Mason-Osann E; Onda M; Pastan I
    J Immunol; 2015 Feb; 194(4):1695-701. PubMed ID: 25560410
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
    Scales SJ; Gupta N; Pacheco G; Firestein R; French DM; Koeppen H; Rangell L; Barry-Hamilton V; Luis E; Chuh J; Zhang Y; Ingle GS; Fourie-O'Donohue A; Kozak KR; Ross S; Dennis MS; Spencer SD
    Mol Cancer Ther; 2014 Nov; 13(11):2630-40. PubMed ID: 25249555
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
    Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
    Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.